Presidential Addresses are not notable for the ventilation of new ideasindeed the office of President, as at present filled, almost guarantees that novelty will be at a discount in any communication from the Chair. I fear that I shall prove no exception, but take comfort when I recollect Oliver Wendell Holmes's observation that 'the first whispers of a new truth are not caught by those in need of an ear trumpet'. Presidential Addresses nevertheless have their uses. They provide a platform from which a man may review the professional interests of his life and draw from his experience what lessons it suggests to him; and this I propose to do. I shall discuss the series of cases on which Thackray and I started in 1947 to investigate the role of the internal mammary lymph nodes in the local spread of breast cancer. This may appear a somewhat outmoded topic when it seems that the biological factors of tumour malignancy and host resistance are the fashionable talking points. I agree that the biological factors are more important in determining the outcome of a breast cancer than the minutia ofits lymphatic spread; and that the problem of malignant cells in the blood stream is a more challenging one than the presence of malignant cells in the lymphatics. Nevertheless, the only two modes of treatment which have shown substantial success surgery and radiotherapyare local forms of treatment. Both can deal only with local spread and it is still worth while therefore to study the way in which breast cancer spreads in the immediate locality of its origin. When a systemic method of treatment is discovered and we can cure breast cancer by pills or injections, local lymphatic spread will become a matter of mere academic interest. Until that day arrives, these details must be of importance to the surgeon and the radiotherapist.
My interest in the internal mammary lymph nodes was stimulated by my father, who had produced clinical evidence that these nodes were much more often affected than generally supposed. This interest was much increased when, shortly before the outbreak of war in 1939, I did a post-mortem examination on a patient who had died a few days after radical mastectomy; I discovered, on looking at the inner side of the manubrium sterni, that an internal mammary node was invaded by the carcinoma and was obviously untouched by the operation which had been done. It seemed that here was a problem which nobody had investigated systematically. There was no time or opportunity between 1939 and 1945 for pursuing this idea and it was not until 1946 that I was able to start, in collaboration with Alan Thackray as histologist, to look into the frequency with which carcinomatous metastases were found in the internal mammary nodes, by doing intercostal space biopsies which were intended not as therapy but as a pathological reconnaissance. The series of patients on whom this has been done has now reached just over 900.
Before embarking on my main topic, I will consider briefly the history of the internal mammary nodes and the way in which they have been mentioned at intervals in the past 180 years, without serious notice being taken, until the last few years, of the lone voices which raised the matter.
The first indication that anatomists had discovered the internal mammary lymph nodes was the illustration of them in Mascagni's magnificent atlas of lymphatic anatomy, published in Siena in 1787 (Fig 1) . The dog-latin in which his text is written has defied my efforts, and those of Miss Evans of the Royal Society of Medicine Library staff, to translate it, and to know whether Mascagni knew that the breast drained into these nodes. The first mention of them in English was by W C Cruikshank and he is generally credited as being their discoverer in the Englishspeaking world. The second edition of his book, 'The Anatomy of the Absorbing Vessels', was published in 1790, the first edition making no mention of the internal mammary nodes. Whether Cruikshank ever saw Mascagni's book is not known, but I have not found Mascagni's name mentioned by Cruikshank, though I must admit that I have not read Cruikshank from cover to cover. Cruikshank was a Glasgow graduate who came to London to work in the Hunter School of Anatomy, and I think that we can at least credit him with the independent discovery of the nodes. The following passages from his book are the relevant ones in this present context:
(1) 'The absorbents of the breasts of women form, like the arteries and veins, two sets; one accompanying the external thoracics, and the other accompanying the internal thoracics, or mammary arteries and veins.'
(2) 'Mammary glands. These are smaller than the former and, like their vessels, are situated by the sides of the mammary veins, at small distances from each other, to the number, sometimes of ten or twelve; I have seldom seen them diseased, except in scrophulous children, and they are commonly so small, as to escape cursory observation.'
(3) 'The internal, or mammary absorbents, arise from the posterior part of the mamma, perforate in many places the intercostal muscles, and join the plexus already described as coming from the liver and diaphragm, and running on each side of the mammary artery and veins, behind the cartilages of the true ribs. The absorbents of the breasts of women and their glands are of immense importance in the practice of surgery.'
(4) 'The case is equally or perhaps more hopeless, if the mammary absorbents have carried the poison to glands within the chest, out of reach of surgery, the patient then must die.' This very clear statement remained generally unnoticedfor nearly 100 years, though scattered references exist before that date. It was not until 1880 that the editions of Gray's Anatomy began to state that the breast drained some of its lymph into the internal mammary nodes. The first surgical reference I found was by Roger Williams in his textbook of 1894, when he commented that it was strange 'that cancerous dissemination does not affect these glands more frequently than it appears to do". In 1898 Marmaduke Shield wrote in his book: 'The communication between the perforating lymphatics and the mediastinal glands and lymphatics of the pleura is very important, and from analogy there is reason to fear that these structures may be implicated in cases of cancer of the breast far earlier than is generally known or believed.'
In the same year of 1898 came the first attempt at surgical treatment of the internal mammary nodes. A house surgeon of Halsted'sa promising young man called Harvey Cushingcleared out (in Halsted's words) 'the mediastinum of one side for recurrent cancer. It is likely I think, that we shall, in the near future, remove the mediastinal contents at some of our primary operations.' This thought of Halsted's never seems to have borne fruit.
No doubt the difficulty of the surgical approach to the internal mammary nodes, before the days of positive pressure anesthesia or of antibiotics, deterred consideration of this awkward problem. It was belittled by such eminent authorities as Poirier, Cuneo & Delamere who stated in 1903: 'It is important to remark that we must not exaggerate the importance of this internal mammary channel. Though its presence is anatomically indisputable, facts none the less show that in the early stages of cancer of the breast, the invasion of the retro-stemal glands is exceptional. The fact that these glands are not usually involved is probably to be explained by the atrophy of this channel in senile mamma, in which cancer usually develops.'
This passage contains a message, in addition to its technical content; it shows how a hypothesis can undergo instant conversion into a law by the use of the words 'facts none the less show' whenin factthere are no facts. I think it fair to claim that my father reawakened interest in the internal mammary lymph nodes. He stimulated Stibbe, the anatomist, to reinvestigate these nodes in 1918, and in the second edition of his book recalled how he had explored the anterior intercostal spaces in 6 patients and found tumour in 2 of them (Handley 1922) . This led him to advocate implanting radium tubes in the anterior ends of the upper three spaces as part of the routine of radical mastectomy, and this was the first serious attempt to grapple with the problem. I have already related how it stimulated Thackray and me to what follows.
There are some details about my series of 900 breast cancer patients which I must mention. All were intended to be the first primary breast cancer, untreated prior to operation. Five of the 900 do not in fact measure up to this. One received prior radiotherapy and 3 patients were counted twice because their second primary tumour was reckoned to be a fresh case; in one of these 3 this was a fair assumption because the histology of the two sides was different. The fifth patient was operated on for a second primary, the first side having been done thirty years before by my father. These 5 in a group of 900 make no difference to percentages; and the difficulty of extracting them is so great that I have left them where they are.
Three patients died after operation, one of a Gram-negative septicwmia and two of pulmonary embolusan operative mortality of 0 3 %. I operated on 70 % of the series and my registrars on the remaining 30 %, and I find that my percentage of positive internal mammary nodes is about twice that of my assistants -a point Table 1 .
The site of the primary tumour was also found to have a profound bearing on internal mammary node invasion. Fig 2 shows that tumours in the inner hemisphere and central area of the breast metastasize to the internal mammary nodes rather more than twice as often as do primary tumours in the outer hemisphere.
A third factor of great importance is the state of the axillary lymph nodes. In the 405 patients whose axillary nodes were free from tumour on histological examination, only 35 (or nearly 9 %) showed internal mammary node invasion. 900 Of the 495 whose axillary nodes were invaded, 174 patients (or 35%) had internal mammary deposits.
A fourth factor which influences invasion of the internal mammary nodes is the size of the primary tumour. If the clinical measurement of the tumour did not exceed 2 5 cm, the invasion rate was 15 %. Tumours over 2-5 cm but not exceeding 5 cm in size showed a 28 % invasion rate; and tumours over 5 cm in diameter showed a 45 % invasion rate (Table 2) . All these figures are in close accord with those recently published by Haagensen (1971) in the second edition of his great book. I agree with his emphasis on the fact that only in clinical Stage A carcinomata, where the tumour is not larger than 2-5 cm in diameter and is situated in the outer hemisphere of the breast, and where the pathologist finds no tumour in the axillary nodes, is it reasonably certain that the internal mammary nodes are free from invasion. My present opinion is that all other patients should have prophylactic irradiation to the parasternal area unless the 495 In correlating internal mammary invasion with prognosis, I shall consider only ten-year results because there seems to be good evidence that from this time onwards the mortality curve for breast cancer patients, having at first dipped steeply, now runs parallel with the mortality of the female population in general. Haagensen's chart (Fig 4) shows that from the 9th year onward the mortality curve for his 626 primary carcinomata treated by radical mastectomy runs parallel with the mortality curve of the general female population in New York State. Others have arrived at the same conclusion, and though recurrences are seen after ten years of trouble-free life, they arTe unusual. It is generally conceded that a five-year follow up is too short to be suited to the average progression of breast cancer; and if one uses a fifteen-year follow up, all the other diseases of which people die have sufficient time to operate and interfere with the accuracy of the mortality figures arising from recurrent cancer. There are 400 of my 900 cases whose ten-year follow up is complete, with the exception of 5 patients who vanished and are counted as dead. Table 3 shows the results. When no nodes are involved 71 % of these patients are alive, 66% having had no sign of recurrence. When both axillary and internal mammary nodes are involved 11 % are alive, 7 % having had no recurrence. When either the axillary nodes or the internal mammary nodes alone are involved, the position in both cases is intermediate between the two extremes, with slightly under 40 % alive without recurrence. I think these figures do show how knowledge of the internal mammary node status divides that group of patients with axillary deposits into two separate categories, one with a modest hope of success, the other with almost no u0 1-1-.1 ., .1. .1 .1 I--: column represent those patients who appeared to have died of something other than breast cancer. This is always a problem in follow-up studies. The great majority of patients dying have no postmortem examination and it is impossible therefore to say for certain why they died. But in all the tables, every patient who is dead is counted as dead of her cancer, even one woman who was well when seen a few months before bathing in the sea at Clacton and who, while drying on the beach, became unconscious and died within a few minutes; we were never able to discover whether the coroner ordered a post-mortem and, if so, what was the result.
A maturing series of cases, of the size now presented, offers the interesting chance of testing various propositions which have been made about the behaviour and treatment of breast cancer. I have not yet ended the analysis of my series, but will consider a few of the things tested.
Delay andPrognosis
Much emphasis has been laid in programmes of public education on the point that the earlier a tumour is treated the more likely it is to be cured. This seems self-evident, but voices have been raised, most notably by Sutherland (1960) , to suggest that the effect of early treatment may not always be as dramatic as is generally suggested.
My own evidence is contained in Table 4 . The first column shows that the difference in the crude five-year survival figures is astonishingly small, particularly when it is realized that the last group, who waited ten or more months, should have the waiting time of about one year added to their total survival timeit is clearly survival time from the first symptom rather than survival from operation which is of greater importance to the patient. Column 2 shows the ten-year survival; this does begin to show the result which might be expected but it is not as marked as one might have hoped until one reaches the long-delay group. Even here the figure of 26% is surprising because it might have been supposed that all would be dead.
Column 3 shows the survival at fifteen years. It here appears that delay has no effect on survival, but the number of patients in the various groups is perhaps too small for any very definite conclusion.
If we analyse this same series of patients to see what effect delay has on clinical staging at the first consultation, we find almost the same lack of correlation between delay and stage. Table 5 reveals perhaps slightly more relationship between these two factors but not much. The same may be said of the effect of delay on histological findings in the axillary and internal mammary lymph nodes (Table 5 ). The figures just presented are of course biased, primarily by the biological nature of the tumour. It is general experience that cancers vary enormously in their malignancy. The highly malignant grow quickly and sound the alarm which takes the patient to her doctor quickly. Bloom (1965) has shown that there are more tumours of high grade malignancy in the short-delay group than in the long-delay group. In an analysis of 1 263 cases he found 23% of low-grade and 32% of high-grade tumours in those delaying less than three months, whereas the corresponding figures were 35 % and 24 % for the group delaying between 1 and 2 years. Even here the difference does not seem sufficiently great to afford a fully satisfactory solution of the riddle. One cannot help thinking that half the equation may be missing if no account is taken of host resistance to the tumoura factor which to the best of my knowledge has never been susceptible to accurate measurement in human beings. There is also a tendency for women (most of whom know, from articles in the popular press, the potential significance of breast lumps) to feel ashamed of having concealed symptoms, and they thus tend to give a falsely short history. This must make a patient's statements about the duration of symptoms suspect when judging accurately the effects of delay in treatment on ultimate result.
These results do not make me feel that we ought to relax our efforts to get patients to treatment as early as possible, but they do suggest that such facile optimism as the view that the mortality of breast cancer could be reduced to one-seventh of its present size by adequate treatment within a month of the onset of symptoms is not credible. The situation was ably, and in my view correctly, summed up by Kreyberg (1953) when he said: '. ... a diagnosis as early as possible is of great importance to a certain, yet unknown, number of individual breast carcinoma patients. As we do not beforehand know who will benefit and who will not, a general plea for "early diagnosis" is fully substantiated, as every individual salvaged is important. We must, however, always have in mind that the benefit is statistically moderate, and we ought to be modest in our claims as to the possibility of materially altering the situation for the breast carcinoma patients by this approach to the problem.'
Age andPrognosis It has often been maintained (and indeed has been my firm impression) that the younger the patient the more malignant was her tumour likely to be.
I think that Table 6 shows this to be the case. Both at five years and ten years, survival is shortest in patients under 40 years -shorter even than those over 70 even though these latter will also suffer from the diseases of old age. The outlook seems best in the 40 to 50 age group. But taking Table 6 as a whole, it is perhaps surprising that the differences are not greater than they are, as I had confidently supposed they would be before I did my analysis. It must, however, be remembered that these figures are not adjusted 
Clinical Staging
Some form of clinical staging, even if performed more or less subconsciously, is essential in the decision as to the appropriate treatment, and has the added fringe benefit of classifying patients when differing forms of treatment in different places are to be compared. The TNM system is now the most popular, but I have always disliked it because I cannot remember its complexities, and because it gives an aura of mathematical accuracy to a process which is approximate and based on the uncertain foundation of clinical examination of the axilla. I have always used Dr Haagensen's Columbia system because I can carry its criteria in my head, and it is simple.
With the help of Mr Richard Garnham, I compared the prognostic guidance which the two systems gave at ten years in 250 patients ( Fig 5) . In Stages A (or 1) and D (or 4) there is little to choose between the systems but Stages B and C show a much better spread with the Columbia system. Indeed the TNM system shows scarcely any difference between Stages 1 and 2 at ten years. I claim for the Columbia system, therefore, not only the advantage of simplicity but also that of accuracy.
Location ofPrimary Tumour andPrognosis
The final question was whether tumours in the inner hemisphere of the breast were more fatal than those in the outer hemisphere. Out of the 400 patients whose ten-year follow up is complete, 342 underwent radical surgery, and it seemed proper to consider only these, as their treatment was approximately similar. At ten years 52% of the 108 patients with tumours in the inner hemisphere were alive, and 53% of the 187 with tumours in the outer hemisphere; however, only 38 % of the 47 patients with central tumours were alive (Table 7) . This does seem to show that only a central position of the tumour has any real bearing on prognosis.
Conclusions
What are my conclusions about this extraordinary disease which, the more one studies it, one seems to understand the less ?
It seems to me, from the evidence put before you, that the histological state of the lymph nodes gives one a better idea of what is likely to happen to a patient in the earlier, or operable, stage of her disease than any other criterion. Considerable accuracy is added to the prognosis by knowledge of what is happening in the internal mammary nodes as well as in the axillary nodes. While internal mammary invasion by itself seems to carry the same significance as invasion of the axilla alone, a double invasion is of very grave prognostic consequence, and indicates that local spread is far advanced. I do not think that adding a surgical excision of the internal mammary nodes to a conventional radical mastectomy is likely to help. I believe that the outcome of a breast cancer from the patient's point of view is largely determined by luck. It depends on the malignancy of the tumour and on how competent is the patient's resistance to it; and only to a much smaller extent on factors which are, at the present time, under human control, namely the time lag between the appearance of tumour and its treatment, and the actual nature of the treatment itself. Sir Hedley Atkins said, at a meeting of the Association of Surgeons in 1953, that the method of treatment made a difference to the end result in only some 10% of patients, and I agree with this estimate. I believe that the reason why we often fail to obtain a cure, even in the apparently favourable case, is that tumour cells get into the blood at a very early stage-perhaps even before the tumour is clinically detectable. These tumour cells suffer an enormousand with luck a totalmortality, and their presence is by no means synonymous with a successful metastasis. Every now and then, however, a tumour embolus establishes itself in the early stages and the primary treatment must then fail. There is a good deal of evidence to support this view. Studies of tumour cells in the peripheral blood of patients with malignant disease have been conflicting, but almost all of them have reported some positive results. If an observer can ever discover a circulating cancer cell in a 10 ml sample of blood taken over a period of perhaps 30 seconds, it seems reasonable to suppose that if, by some magical means, the whole blood volume could be scanned for tumour cells the whole time, the presence of malignant cells would be the usual, rather than the exceptional, finding. There are also other pieces of evidence that point in this direction, notably Galasko's demonstration, by the use of F 18 and the gamma camera, that 12 of his 50 early cases of breast cancer showed osseous metastases when conventional radiology had failed to detect any bony changes (Galasko 1969). My contention is also supported by the paper of Roberts and his colleagues (1967) who found no difference in prognosis (in a group of 749 patients) whether circulating cancer cells were found or not; my own inference being that, had the right sample of blood been taken at the right moment, all would have been positive.
It seems clear that we do not yet know the best method of treating so-called early breast cancer. Many trials are at present going on and, if Sir Hedley Atkins is right in the opinion quoted, it will take a very large trial and a very long time to discover, from the 10% of patients in whom treatment does make a difference, what is the correct method. I meanwhile continue in my belief that a long transverse incision, the removal of sufficient skin, thin skin flaps, preservation of the pectoralis major muscle, radical clearance of the axilla, and frequent skin grafting, are rational; and that the quality of the patient's life is thus improved without sacrifice of its quantity. I believe that this conservative radical mastectomy as described by Patey & Dyson (1948) diminishes the local recurrences which simpler techniques involve, without causing the deformity entailed in more radical operations.
My final conclusion is that we should not be too pessimistic about the good we do by treating our breast cancer patients. I think the most cheering paper on breast cancer that I ever read was that of Bloom, Richardson & Harries (1962) , wherein they recorded the survival of 250 untreated cases of breast carcinoma. Their source was the records of the Middlesex Hospital Cancer Charity, carefully kept from the inception of the charity in 1794 to relatively recent times. In each of these 250 patients, the date of the first symptom, the progress, the date of death and the post-mortem report were available, though (there being no histology over most of the period) very few microscopic reports were available. Only 2 cases were alive at fifteen years and all were dead at twenty years. By contrast 61 of my first 200 patients are alive at fifteen years, only 4 of them showing evidence of recurrence. Whatever the selection exercised, surely a 30% survival at fifteen years is better than an 0 3% survival. We do achieve something by treatment.
